Supreme Court Reviews Generic Drug 'Skinny Labeling' Case, With Major Cost Savings at Stake
Similar Articles
Supreme Court Weighs Federal vs. State Authority on Pesticide Warning Labels
FDA to Review Peptide Access as Market Anticipates Regulatory Shift
Trump Administration Finalizes Drug Pricing Deal with Regeneron
CMS Announces Medicare GLP-1 Bridge Program for Weight Loss Medications
Supreme Court Temporarily Restores Mail-Order Access to Abortion Pill Mifepristone
The Supreme Court is hearing a case that could affect the future of 'skinny labeling,' a strategy used by generic drugmakers to bring cheaper medications to market for specific, unpatented uses. The practice has saved billions for patients and government programs like Medicare, but a brand-name manufacturer is alleging a generic competitor encouraged use of its drug for a still-patented purpose.
Facts First
- The Supreme Court is hearing the case Hikma v. Amarin on Wednesday.
- The dispute centers on 'skinny labeling,' a strategy generic firms use to market cheaper drugs for unpatented uses.
- Skinny labeling has saved Medicare nearly $15 billion between 2015 and 2021.
- Generic medications account for nine out of every 10 prescriptions in the United States.
- Americans pay less for generic medications than people in any other peer nation.
What Happened
The Supreme Court is hearing the case Hikma v. Amarin on Wednesday. Hikma is a generic drugmaker and Amarin is the maker of Vascepa, a brand-name drug made from purified fish oil for people at high risk of heart disease. The dispute centers on 'skinny labeling,' a strategy used by generic firms to bring cheaper medications to market for unpatented uses of a drug. Amarin patented Vascepa for two patient groups: those at very high risk for heart disease and those at lower risk. Hikma entered the market with a skinny label approval for Vascepa in 2020 after the use for higher-risk patients went off patent. Amarin sued Hikma, alleging Hikma encouraged doctors to prescribe the generic for the still-patented use by describing the product as a 'generic version' of Vascepa without flagging its narrow approval. A federal circuit court previously ruled in favor of Amarin, but the Supreme Court agreed to review the case.
Why this Matters to You
If you or someone you know relies on prescription medications, this case could affect the cost and availability of generic alternatives. Generic medications currently account for nine out of every 10 prescriptions in the United States, and on average, Americans pay less for them than people in any other peer nation. The skinny labeling pathway has been used for more than two dozen copycat medicines over the last decade, including the cholesterol-lowering pill Crestor. A study found that skinny labeling saved Medicare nearly $15 billion between 2015 and 2021. According to a trade group representing generic manufacturers, the copycat version of Crestor saved patients and insurers more than $8 billion in just one year. A Supreme Court decision against the practice could potentially reduce these savings and limit future generic competition for certain uses of brand-name drugs.
What's Next
The Supreme Court's decision will determine the future legal framework for skinny labeling. Data shows the Supreme Court overturns lower court decisions approximately 70% of the time, but the outcome of this specific case is uncertain. More than 70 legal scholars and the Trump administration's solicitor general filed briefs in defense of Hikma, and the solicitor general also pushed the Supreme Court to take the case. The ruling could clarify the rules for how generic manufacturers market their products and may influence whether other drugs, like Crestor, which saw competition launch in 2016 despite patents that could have lasted until 2022, continue to benefit from this pathway.